Principles of Care for Immune Therapies in Multiple Myeloma

This resource offers strategies to healthcare teams for managing immune therapies in multiple myeloma, particularly CAR T-cell therapy and bispecific antibodies. As these innovative treatments reshape care pathways, clinicians must navigate distinct toxicity profiles, inpatient vs. outpatient protocols, and evolving practices. Drawing from both IMWG consensus guidelines and emerging clinical insights, we offer “living principles” for identifying and managing complications like cytokine release syndrome and neurotoxicity.